# If Bristol-Myers Squibb Company moves, who benefits? How far does the value-chain ripple reach?
Canonical: https://valuechain.wiki/bristol-myers-squibb · Facet: ripple · Updated: 2026-09-11T18:43:29.256621+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Per the valuechain.wiki graph, Bristol-Myers Squibb Company is directly linked to 6 companies (1 supply, 5 revenue relationships) and reaches 9 companies within two hops; the links are backed by 9 dated sources, 4 of them primary filings (as of 2026-09-11).

Bristol-Myers Squibb Company operates across Global biopharma portfolio. It is +28.1% in 2026. The stock (+28.1%) is ahead of both its demand side (avg -63.9%) and supply side (avg -17.1%). Having run ahead of its chain, it is the first spot to give back if customer numbers fail to follow. Among connected nodes the furthest ahead is Samsung Biologics (-17.1%) and the furthest behind is ABL Bio (-63.9%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. It uses external manufacturers such as Samsung Biologics and Cellares for parts of its supply network and deploys capital to acquire new growth assets.

## Demand chain (leading)
- T1 ABL Bio (https://valuechain.wiki/abl-bio.md)
- T2 Lilly (Eli) (https://valuechain.wiki/lilly-eli.md)
- T3 Cardinal Health, Inc. (https://valuechain.wiki/cardinal-health.md)
- T3 McKesson Corporation (https://valuechain.wiki/mckesson.md)
- T3 Cencora, Inc. (https://valuechain.wiki/cencora.md)
- T1 Regeneron Pharmaceuticals (https://valuechain.wiki/regeneron-pharmaceuticals.md)

## Supply chain (benefiting)
- T1 Samsung Biologics (https://valuechain.wiki/samsung-biologics.md)
- T2 Samsung E&A (https://valuechain.wiki/samsung-e-a.md)
- T3 Ecopro HN (https://valuechain.wiki/ecopro-hn.md)
- T2 Danaher Corporation (https://valuechain.wiki/danaher.md)

---
Full node: https://valuechain.wiki/bristol-myers-squibb.md · JSON: https://valuechain.wiki/bristol-myers-squibb.json